Two-thirds of respondents believe setup and training on trial sponsor technology are more problematic than five years ago.
Advarra revealed findings from its 2023 Study Activation Survey indicating increases in site burden since 2018. According to the report, around 60% of sites say their study volume is higher plus they are managing more sponsor-provided technology, which was rated a higher burden than contracting and budgeting. Furthermore, 55% of sites report setup and training on sponsor technology to be extremely or very burdensome, and 67% say it's gotten worse in the past five years.
"Sites are increasingly saddled with complex technologies and duplicative, administrative tasks.We need to come together as an industry and support both sites and sponsors with technology that works for each stakeholder respectively and helps improve clinical research – not hinder it," said Gadi Saarony, CEO, Advarra."Advarra uniquely knows and understands the needs of sponsors, CROs, sites, and participants and is committed to driving industrywide stakeholder collaboration and to be the pioneer in connecting the clinical research ecosystem."
Reference: New Clinical Trial Industry Survey Reveals Increased Burdens on Sites. PR Newswire. October 17, 2023. Accessed October 19, 2023. https://www.prnewswire.com/news-releases/new-clinical-trial-industry-survey-reveals-increased-burdens-on-sites-301958244.html
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.